Back to Results

A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

Must have a lesion of sufficient size to support injection of complete first dose of mRNA-2752

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Antonio Jimeno,  MD

Antonio Jimeno, MD

Study ID

Protocol Number: 18-1526

ClinicalTrials.gov: NCT03739931

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers